AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06191952 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cognigram
Description: Cognigram (previously known as the Cogstate Brief Battery) is a brief, computer-administered cognitive test battery requiring about 20-25 minutes for administration, consisting of four cognitive tasks to measure psychomotor function, attention, working memory, and learning and memory. Eisai owns the commercial rights for Cognigram and has kindly agreed to offer the required licenses for the present project free of charge. Digital cognitive testing will take place in the respective social and care centers on a tablet which is not connected to the internet. Testing will be performed pseudonymized and data from the cognitive tests will be downloaded regularly by the study team and added to the database at LMU hospital.
Study NCT06191952 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Subjective cognitive decline questionnaire (SCD-Q)
Description: The SCD-Q is a validated questionnaire assessing the presence of subjective cognitive deterioration in abilities such as memory, attention, language, and executive function. The scale includes 24 dichotomous questions (yes/no), evaluating decline in daily life during the last two years. The SCD-Q score ranges from 0 to 24, with higher scores indicating greater perceived cognitive change (cut-off classified as SCD equal or greater as 7).
Study NCT06191952 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood-based biomarkers
Description: Blood plasma and serum samples will be collected by the project staff according to standard operating procedures used at LMU Munich and subsequently processed and measured at the Department of Psychiatry and Psychotherapy to quantify the blood-based biomarkers for AD using Elecsys immunoassays running on a Cobas e402 analyzer. All test results (including the respective cut-off measurements for normal vs abnormal) will be forwarded directly to the participants' GPs. No further explanations and instructions will be provided to avoid any unwanted bias, and participants will only be informed about their results by their doctors. Roche has kindly offered to provide blood biomarker assays free of charge for the present project.
Study NCT06191952 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ki:elements digital speech biomarker for cognition (ki:e SB-C)
Description: The ki:elements digital speech biomarker for cognition (ki:e SB-C) can be collected remotely in fully automated telephone visits, taking 15 minutes to complete based on three specific assessments measuring learning and memory, processing speed, executive function, and language capabilities. The ki:e SB-C uses artificial intelligence and automatic speech analysis to process and transcribe speech, followed by an extraction of relevant features, combined into four subdomain and one global cognition score.
Study NCT06428123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy on present Lower Limb
Description: Patients will be seated close to a table on which a mirror will placed vertically. The normal (i.e., no amputated limb) will be placed in front of the mirror and made to perform movements of the different joints while the patient looking into the mirror.
Study NCT06428123 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mental Imagery on present Lower Limb
Description: Mental imagery technique in which patients will be instructed to concentrate on sensations from each area of the body, including the phantom limb. Patients will be advised to imagine comfortable, thorough movement and sensation in the phantom limb, such that they could stretch away the pain, and finally to allow the limb to rest in a comfortable position. The actual therapy of moving and feeling the limb will lasted for 5 minutes. Patients will be asked to perform 40 minutes of meditation and imagery exercises.
Study NCT05680246 — intervention group
Intervention type: DEVICE
Intervention: DHOPE-PRO
Description: Prolonged DHOPE preservation >4 hours
Study NCT06463470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)
Description: CBT-AR describes an adaption of cognitive behavioural therapy for use with individuals diagnosed with Avoidant/Restrictive Food Intake Disorder (ARFID).
Study NCT05401500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sampling
Study NCT04208516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Quadratus Lumborum Nerve Block
Description: To be administered to subjects in the active comparator group receiving primary major abdominal surgery.
Study NCT04208516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Erector Spinae Plane Nerve Block
Description: To be administered to subjects in the experimental group receiving primary unilateral thoracic surgery.
Study NCT04208516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Quadratus Lumborum Nerve Block
Description: To be administered to subjects in the experimental group receiving primary major abdominal surgery.
Study NCT04208516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: To be given postoperatively as a continuous infusion at a dose of 50 mg/hr in the experimental group.
Study NCT04208516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: To be used in both treatment arms as nerve block initial bolus injection.
Study NCT04208516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: To be used in both treatment arms as nerve block initial bolus injection.
Study NCT04208516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.
Study NCT04208516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.
Study NCT04208516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: To be used perineurally as a 0.25% solution in the active comparator group at a rate of 10 ml/hr per perineural catheter.
Study NCT05959109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peresolimab
Description: Administered SC
Study NCT06143488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular therapy
Description: Drug: Best medical management All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.~Procedure: Endovascular therapy In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment.
Study NCT06143488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Description: Drug: Best medical management All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.~Procedure: Endovascular therapy In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment.
Study NCT06143488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best medical management
Description: All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
Study NCT06135285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control subjects
Description: The subject will be repositioned from the prone to recovery position
Study NCT06103526 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Immunonutrition
Description: enteral supplementation with high amount of proteins, arginine, glutamine, nonessential fatty acids, branched chain fatty acids, nucleotides, or RNA
Study NCT05144620 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D Mapping
Description: 3D model will be made from diagnostic imaging for pre-surgical planning
Study NCT05287659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: meal replacements or supplementation with leucine
Description: meal replacements or animal protein or supplementation with leucine
Study NCT05287659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: meal replacements or supplementation with leucine
Description: meal replacements or animal protein or supplementation with leucine
Study NCT05763628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens (stenfilcon A)
Description: Daily Disposable Multifocal Contact Lens for 2 weeks
Study NCT05763628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens (senofilcon A)
Description: Daily Disposable Multifocal Contact Lens for 2 weeks
Study NCT05853679 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lumoral Treatment
Description: The device will be used 5 to 7 times per week according to the manufacturer's instructions.
Study NCT05853679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral Treatment
Description: The device will be used 5 to 7 times per week according to the manufacturer's instructions.
Study NCT05946083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin Intervention
Description: For 6 weeks, 23 binge drinkers will be given a daily dose (divided into three times a day) of 15g of a dietary fiber with benefits for intestinal bacteria (inulin).
Study NCT05946083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin Intervention
Description: For 6 weeks, 23 binge drinkers will be given a daily dose (divided into three times a day) of 15g of dietary fiber with no specific benefits for the intestinal microbiome (maltodextrin).
Study NCT05853679 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard oral hygiene instructions according to the Finnish Dental Association
Description: Participants will be instructed to clean their teeth twice per day by an electric toothbrush, an interdental brush, and flossing.
Study NCT06001788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral administration
Study NCT06580444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brexanolone
Description: The participant will receive either a placebo, or 90, 60, or 30 mcg/kg/hr of Brexanolone over a 20-hour period intravenous infusion.
Study NCT06578975 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HT-ENDO-MOS-A13
Description: Mutli-Omics based biomarker to diagnose primary hypertension or endocrine forms of hypertension; primary aldosteronism, pheochromocytoma/functional paraganglioma or Cushing syndrome.
Study NCT06578975 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normal diagnosis
Description: Standard diagnosis for endocrine hypertension
Study NCT05338099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN001
Description: EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg
Study NCT05338099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN001
Description: EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg
Study NCT06001788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous infusion
Study NCT06001788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Intravenous infusion
Study NCT06001788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous Infusion
Study NCT06001788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Oral administration
Study NCT06001788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Description: Subcutaneous injection
Study NCT06156072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound-guided venipuncture
Description: Venipuncture will be performed using ultrasound to identify the most appropriate vessel and guide the puncture
Study NCT05350241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Split-belt treadmill training
Description: Participants in the split-belt walking group (experimental group) performed repeated split-belt treadmill training with an error-augmentation strategy (exaggeration of the initial step-length asymmetry) for 60 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics.
Study NCT05350241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: Participants in the control group received the standard physical therapy program. Each session lasted for 60 minutes, repeated three times a week, over 12 consecutive weeks. The program consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
Study NCT05199818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron HCl Buccal Film 0.5 mg
Description: Palonosetron HCl Buccal Film and IV palonosetron placebo, both administered on Day 1
Study NCT05199818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Palonosetron 0.25 mg
Description: IV Palonosetron and Palonosetron HCl Buccal Film placebo, both administered on Day 1
Study NCT06434545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Reasoning methodology
Description: Twenty nursing teams will be trained in the Palliative Reasoning methodology during a four hour training, split into two sessions. Additionally, teams receive a coaching session ones a month and practice with a real life case every week or two weeks during a one hour team meeting. This will be compared with 20 other nursing teams that will continue to provide care as usual.
Study NCT02988245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geneticure Panel for HTN therapy
Description: Using either Genetics (Geneticure for HTN multi-gene panel) or JNC-8 guidelines for prescribing for patients with hypertension
Study NCT02988245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNC-8
Description: Using JNC-8 guidelines to guide therapy
Study NCT05288010 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Cannabis
Description: The provision of whole flower cannabis via an inhalation device in addition to standard of care chronic pain treatment.
Study NCT04949659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Description: Laparoscopic appendectomy performed with defined, randomized to level of pressure for pneumoperitoneum
Study NCT06537141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: selective embolization of thyroid arteries (SETA)
Description: selective embolization of thyroid arteries
Study NCT04811261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Infusion of UCLSCs
Description: The first 3 subjects will be administered 50 x 10\^6 ULSCs reconstituted in PBS with 1% human serum albumin in a volume of 250 ml, and monitored for adverse events or toxicities, immediately following dosing, and again at 30 days.
Study NCT04799626 — intervention group
Intervention type: DRUG
Intervention: biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc
Description: biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc extended infusion time or continuous infusion for 24 hours;Tigecycline changed standard does for treatment.
Study NCT06164925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nutrition screening and assessment
Description: The patient is interviewed for changes in body weight in the last six months and food intake in the last two weeks.~The investigator evaluates the patient's diet, symptoms related to their nutritional status, and functional capacity according to the Subjective Global Assessment (SGA). The SGA tool itself is completed by the researcher.~Height and weight of the patient are measured, if not yet recorded, and BMI is calculated.~The patient's muscle mass is measured using mid-upper arm circumference (MUAC), calf circumference (CC) and bioelectrical impedance (BIA), and their muscle function assessed using hand grip strength.
Study NCT05168891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Description: Peri-implantitis surgical therapy by means of open flap debridement, detoxification/decontamination of the implant surface and xenograft regeneration.
Study NCT05168891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical therapy of peri-implantitis
Description: Peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed
Study NCT06545422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: St. John's wort oil
Description: To examine the effect of regularly applied St. John's Wort oil on skin moisture.
Study NCT06545422 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Barrier Cream
Description: To examine the effect of regularly applied barrier cream on skin moisture.
Study NCT04707274 — intervention group
Intervention type: OTHER
Intervention: Survey study
Description: Victorian Institute of Sports Assessment for Gluteal Tendinopathy (VISA-G) Questionnaire will be applied.
Study NCT06230471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab,Lenvatinib and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）
Description: Drug: Pembrolizumab Pembrolizumab 200 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle. Drug: Lenvatinib Oral Product The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of \<60 kg, taken once daily. Drug: Chemotherapy GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks.
Study NCT06230471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and Lenvatinib
Description: Pembrolizumab and Lenvatinib
Study NCT06230471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）
Description: Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）
Study NCT06530511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Polatuzumab: 1.8 mg/kg, IV Drip infusion, D1;
Study NCT06530511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: 375 mg/m2, IV Drip infusion, D1
Study NCT06530511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib: 150 mg/time, qd, po, D1-21
Study NCT05241704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting
Description: Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the ulcer under complete aseptic operative setting
Study NCT05241704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovenous ablation of superficial venous reflux
Description: Endovenous ablation of the main truncal venous reflux to the lowest point of incompetence, where possible (routine practice)
Study NCT05241704 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous ablation of superficial venous reflux
Description: Endovenous ablation of the main truncal venous reflux to the lowest point of incompetence, where possible (routine practice)
Study NCT05294796 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Short course of antibiotherapy
Description: Short duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
Study NCT05294796 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Long course of antibiotherapy
Description: Long duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material